[go: up one dir, main page]

WO2003047629A2 - Traitement de maladies - Google Patents

Traitement de maladies Download PDF

Info

Publication number
WO2003047629A2
WO2003047629A2 PCT/GB2002/005394 GB0205394W WO03047629A2 WO 2003047629 A2 WO2003047629 A2 WO 2003047629A2 GB 0205394 W GB0205394 W GB 0205394W WO 03047629 A2 WO03047629 A2 WO 03047629A2
Authority
WO
WIPO (PCT)
Prior art keywords
agent
individual
composition
molecule
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/005394
Other languages
English (en)
Other versions
WO2003047629A3 (fr
Inventor
Rachid Tazi-Ahnini
Simon Ward
Michael Cork
Gorden Duff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Skincare Ltd
Original Assignee
Molecular Skincare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Skincare Ltd filed Critical Molecular Skincare Ltd
Priority to AU2002365654A priority Critical patent/AU2002365654A1/en
Publication of WO2003047629A2 publication Critical patent/WO2003047629A2/fr
Publication of WO2003047629A3 publication Critical patent/WO2003047629A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Definitions

  • This invention relates to the treatment of diseases. More generally, the invention relates to the delivery of drugs and other agents for various purposes, including topical delivery or delivery of drugs and other agents via the epidermis.
  • Drugs and other agents may be administered to individuals such as patients requiring them in various ways, including oral adm stration, injection, and topical administration.
  • a skin penetration enhancer which is dermatologically acceptable and compatible with the drug into a formulation to increase its penetration from the skin surface into epidermal keratinocytes.
  • a skin enhancer which increases the absorption of the active compound(s) into the skin reduces the amount of agent needed for an effective treatment and provides for a longer lasting effect of the formulation.
  • Skin penetration enhancers known in the art include dimethyl sulfoxide (U.S. Pat. No.
  • the present invention seeks to solve one or more problems associated with prior art methods of drug delivery.
  • a first aspect of the present invention we provide use of an agent capable of effecting the degradation of a component of the epidermal barrier of an individual to enable or assist transdermal delivery of a molecule to the individual.
  • a method of delivering a molecule to an individual comprising: (a) providing an agent capable of effecting the degradation of a component of the epidermal barrier of the individual; (b) administering the agent to the individual; and (c) administering the molecule to the individual.
  • a method of treating a disease in an individual comprising: (a) administration of an agent capable of effecting the degradation of a component of the epidermal barrier of the individual, followed by (b) administration of a drug indicated for the disease.
  • a composition comprising a molecule to be delivered through an epidermal barrier of an individual together with an agent capable of effecting the degradation of a component of the epidermal barrier of the individual.
  • an agent capable of effecting the degradation of a component of the epidermal barrier of an individual for use in a method of treatment of a disease in an individual, in which the treatment comprises administration of the agent to enable or assist transdermal delivery of a drug to the individual.
  • the present invention in a sixth aspect, provides use of an agent capable of effecting the degradation of a component of the epidermal barrier of an individual in the preparation of a pharmaceutical composition for the treatment of a disease in an individual, in which the treatment comprises administration of the agent or the pharmaceutical composition to enable or assist transdermal delivery of a drug to the individual.
  • kits comprising a compound to be delivered through an epidermal barrier of an individual, an agent capable of effecting the degradation of a component of the epidermal barrier of the individual, and instructions for using the agent to effect delivery of the compound.
  • a method of preparing a composition capable of enhanced transdermal delivery of a compound comprising the steps of providing a composition comprising a compound to be delivered, and adding an agent capable of effecting the degradation of a component of the epidermal barrier of an individual to the composition.
  • the compound or molecule to be delivered may be administered simultaneously, sequentially or as a mixture with the agent.
  • the agent is administered to the individual, followed by administration of the compound or molecule to the individual.
  • the agent comprises an agent capable of effecting the degradation of a proteinaceous component of the epidermal barrier.
  • the proteinaceous component is comprised in the stratum comeum.
  • the proteinaceous component comprises an adhesion protein, preferably a desmosomal adhesion protein.
  • the adhesion protein comprises corneodesmosin.
  • the agent comprises a protease.
  • the protease may be selected from the group consisting of: Stratum Comeum Chymotryptic Enzyme (SCC; kallikrein 7, KLK7 ), Stratum Comeum Tryptic Enzyme (SCTE; kallikrein 5, KLK5), aminopeptidase M, carboxypeptidase P, carboxypeptidase Y, caspase 1,4,5, caspase 2,3,7, caspase 6,8,9, chymotrypsin, Factor Xa, pepsin, TEN, thrombin and trypsin.
  • SCC Stratum Comeum Chymotryptic Enzyme
  • SCTE kallikrein 5, KLK5
  • aminopeptidase M aminopeptidase M
  • carboxypeptidase P carboxypeptidase Y
  • caspase 1,4,5, caspase 2,3,7, caspase 6,8,9 aminopeptidase M
  • the agent comprises an antagonist of a protease inhibitor, such as an antagonist of a antileukoprotease or an antagonist of a elafin protease inhibitor 3 (PI3 or SKALP).
  • a protease inhibitor such as an antagonist of a antileukoprotease or an antagonist of a elafin protease inhibitor 3 (PI3 or SKALP).
  • the agent is capable of effecting the degradation of a lipidic component of the epidermal barrier.
  • the lipidic component is comprised in the lipid lamellae.
  • the agent comprises a lipase.
  • More than one agent may be administered. Therefore, a particular embodiment of the method according to the first or third aspects of the invention or a use according to the second aspect of the invention further comprises the step of administering a second agent capable of effecting the degradation of a second component of the epidermal barrier of the individual. Furthermore, a composition according to the fourth aspect of the invention may further comprise a second agent capable of effecting the degradation of a second component of the epidermal barrier of the individual.
  • the first component comprises a proteinaceous component and the second component comprises a lipidic component.
  • the first agent comprises a protease and the second component comprises a lipase.
  • the agent capable of effecting the degradation of a lipidic component and the agent capable of effecting the degradation of the proteinaceous component may be administered in any order.
  • the agent capable of effecting the degradation of a lipidic component is administered before the agent capable of effecting the degradation of the proteinaceous component.
  • degradation of the lipidic component of the epidermal barrier preferably enables the agent capable of effecting the degradation of the proteinaceous component to contact the proteinaceous component of the epidermal barrier.
  • the methods and compositions as described here are useful for enabling or assisting delivery of a molecule to a normal skin.
  • the compound or molecule to be delivered is not normally capable of crossing the epidermal barrier of normal human skin.
  • the methods and compositions as described here may also be used to enable or assist delivery of a molecule to diseased or otherwise abnormal skin.
  • the compound or molecule to be delivered may be one which is capable of crossing the epidermal barrier of normal human skin but not substantially capable of crossing the epidermal barrier of psoriatic skin.
  • any molecule may be delivered according to the methods and compositions as described here.
  • the compound or molecule comprises a drug or other therapeutic compound, preferably ascomycin or tacrolimus.
  • the compound or molecule to be delivered may have a molecular weight of more than about 1000 Daltons.
  • the compound or molecule may have a molecular weight of between about 800 Daltons to about 1000 Daltons.
  • the or each agent is administered or applied in the form of a patch comprising the or each agent or both agents.
  • the patch may further comprise the compound or molecule to be delivered in a separate compartment from the or each agent.
  • the patch comprises a mixture of the or each agent and the compound or molecule to be delivered.
  • the or each agent may be provided in the form of a cream.
  • the cream may further comprise the molecule or compound to be delivered.
  • a patch comprising an agent capable of effecting the degradation of a component of the epidermal barrier of an individual.
  • the agent or component in such a patch may be as defined m any of the preceding aspects of the invention.
  • a patch comprising a composition according to the fourth aspect of the invention.
  • a patch comprising a molecule to be delivered to an individual together with an agent capable of effecting the degradation of a component of the epidermal barrier of an individual.
  • the molecule and the agent may be in separate compartments, or they may be in the form of a mixture.
  • a thirteenth aspect of the present invention we provide the combined use of an agent capable of effecting the degradation of a proteinaceous component of the epidermal barrier together with an agent capable of effecting the degradation of a lipidic component of the epidermal barrier for assisting the transdermal transport of a therapeutic molecule.
  • an agent capable of reducing an epidermal barrier ftinction to enable or assist transdermal delivery of a molecule is provided, according to a fourteenth aspect of the present invention.
  • the methods and compositions as described here involve the use of one or more agents capable of reducing an epidermal barrier function of an individual, to enable or assist, or otherwise effect, the transdermal deHvery of a molecule (i.e., delivery of a molecule across the epidermal barrier of a patient).
  • agents capable of reducing an epidermal barrier function of an individual to enable or assist, or otherwise effect, the transdermal deHvery of a molecule (i.e., delivery of a molecule across the epidermal barrier of a patient).
  • an agent capable of reducing (preferably degrading) an epidermal barrier function to enable increased epidermal transport of a molecule.
  • the individual is a patient suffering or likely to suffer from a disease
  • the molecule is a drag such as a therapeutic or prophylactic drug.
  • the methods and compositions described here are suitable for assisting or effecting the delivery of any molecule as desired, not necessary being of medical or therapeutic benefit.
  • molecules which are for example components of cosmetics may also be delivered by the methods and compositions described here.
  • the agent capable of reducing an epidermal barrier function preferably comprises an agent capable of effecting the degradation of the epidermal barrier (or a component of the epidermal barrier) associated with the stratum comeum.
  • the methods further involve the administration of the molecule, preferably a drug indicated for a disease, to be delivered to an individual (such as a patient).
  • the methods and compositions as described here involve the use of one or more agents capable of effecting the degradation of a component of an epidermal barrier of an individual, preferably a lipidic or proteinaceous component.
  • the agent is one which is capable of effecting the degradation of the epidermal barrier associated with the stratum comeum or the lamellar lipids, preferably the stratum comeum.
  • the agents as described here are capable of effecting the degradation a component of the epidermal barrier; in other words, the component is degraded in the presence of the agent(s), but not substantially in their absence.
  • the agents may directly degrade the component of the epidermal barrier, or indirectly cause the degradation of the barrier. They may therefore comprise molecules, enzymes or other proteins which act to degrade, destroy, abolish or remove the component.
  • the agent may comprise for example a protease or proteinase or any molecule comprising a proteolytic activity; where the component is lipidic in nature, the agent may comprise a lipase or a molecule capable of degrading, breaking down or digesting a lipid.
  • the agent is preferably an enzyme, or a polypeptide having relevant enzymatic activity, such as a fragment of an enzyme.
  • a polypeptide comprising protease activity a polypeptide comprising lipase activity, a fragment of a protease, a fragment of a lipase, a polypeptide comprising a protease active site, a polypeptide comprising a lipase active site, etc. Combinations of any of the above may be employed.
  • the agents may also comprise molecules which act to regulate any of the activities of any of the above.
  • the protease activity and/or lipase activity comprises an endogenous enzyme activity.
  • the protease involved is one which is expressed in the individual concerned, preferably, in the skin of an individual.
  • the lipase involved comprises a lipase expressed in the individual, preferably, expressed in his or her skin.
  • endogenous proteases include S Stratum Comeum Chymotryptic Enzyme (SCCE) and Stratum Comeum Tryptic Enzyme (SCTE).
  • the agent may not itself act to degrade the epidermal barrier, but may act indirectly, for example, by modulating the activity of a protease, lipase or other degrading agent.
  • the agent may comprise a molecule capable of up-regulating the expression of an endogenous protease, for example one as listed above.
  • the agent may comprise a molecule capable of down-regulating the breakdown or degradation of such a protease.
  • Endogenous protease activity may be regulated by protease inhibitors, for example, endogenous protease inhibitors such as antileukoprotease (skin-derived antileukoprotease) and elafin protease inhibitor 3 (PI3 or SKALP).
  • the agents may comprise molecules capable of down-regulating the activity of protease inhibitors, preferably endogenous protease inhibitors.
  • the skin is a barrier that retains water within the body and prevents the penetration of environmental agents into the body.
  • the barrier function of the skin is essential to the maintenance of the internal homeostasis (Cork 1997).
  • the epidermis is composed of layers of closely packed keratinocytes that are formed by division in the stratum basale (or germinative layer). As the keratinocytes move up through the prickle and granular layers, they differentiate and a rigid internal structure of keratin, microfilaments and microtubules is formed.
  • the stratum comeum (homy layer) is composed of layers of flattened dead cells that have lost their nucleus, between which is a complex mixture of lipid and proteins.
  • the "barrier function" of the epidermis, or the “epidermal barrier function”, as the terms are used in this document, is therefore intended to refer to the ability of an epidermal layer to resist the penetration of an external agent.
  • the epidermal permeability barrier provides a barrier to the penetration of drags through the stratum comeum and into the viable part of the epidermis. Once a drag has passed through the stratum comeum it has a passage to the rest of the body. Drags of more than 1000 daltons molecular weight will not normally pass through an intact epidermal permeability barrier. Drags of molecular weight 800-1000 may pass through the normal epidermal barrier but this is variable and influenced by several factors including the structure and lipid solubility.
  • stratum corneum is a barrier that is continually being replaced by proliferation and differentiation of keratinocytes in the viable epidermis.
  • stratum comeum thickness In order to maintain a constant stratum comeum thickness at a given body site superficial parts of the stratum comeum must be continuously shed in the process of desquamation at a rate that balances their production.
  • the barrier function or epidermal barrier may comprise one or more components, any number of which are degraded, individually or together, by the methods and compositions as described here.
  • Particularly preferred components of the epidermal barrier comprise proteinaceous components and lipidic components. Such components of the epidermal barrier are described in a separate section below.
  • An epidermis which has been treated with an agent capable of reducing an epidermal barrier function for example, an agent capable of effecting the degradation of a component of the epidermal barrier, has an reduced epidermal barrier function.
  • an agent capable of reducing an epidermal barrier function for example, an agent capable of effecting the degradation of a component of the epidermal barrier, has an reduced epidermal barrier function.
  • the molecular weight cut-off of the epidermal barrier is increased, so that molecules of higher molecular weight are able to cross the skin than an untreated skin.
  • transdermal is meant to encompass passage of a molecule across the epidermal barrier of an individual.
  • the methods and compositions described here therefore enable the delivery of a molecule to any portion of the body of an individual which is below the epidermal barrier, for example, a subcutaneous portion, a sub-epidermal portion, a muscle portion or a fat portion of the body.
  • An epidermis treated by the methods and compositions as described here is more permeable to an external agent than a corresponding untreated epidermis.
  • the corresponding epidermis is preferably one from the same patient, individual or animal, for example, an epidermis from another part of the patient, individual or animal.
  • the corresponding epidermis has the same disease state or normality as the one which is treated.
  • the corresponding epidermis may also be derived from another individual, etc.
  • a suitable reference material may comprise untreated psoriatic skin from another part of the body of the same individual, or psoriatic skin from another individual.
  • an epidermis which has been treated by the methods and compositions described here will typically have a reduced or impaired barrier function, and will allow more penetration of an external agent than otherwise.
  • the untreated sldn may be substantially impermeable to the external agent of interest.
  • the agent capable of effecting the degradation of a component of the epidermal barrier enables an amount of external agent to pass through the epidermal barrier.
  • the treated sldn may have such a degraded epidermal barrier that the skin becomes substantially completely permeable to the external agent.
  • the epidermal barrier is broken down to such an extent that the amount of agent capable of passing through the barrier is more than in an untreated sldn.
  • the epidermal barrier is broken down to such an extent that a desired amount of agent may be delivered, preferably a therapeutically effective amount of agent.
  • a treated epidermis is 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% 90%, 100%, 200%, 300%, 400%, 500%, 10 times or more permeable to an external agent than an untreated epidermis.
  • Increase in penetration or permeability is preferably reflected by increase of mass of agent or drag, activity of an agent or drag (such as a relevant chemical, biological or enzymatic activity) which passes through the epidermal layer.
  • a treated epidermis will therefore preferably enable penetration of 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% 90% or 100% or more agent or drug than an untreated epidermis.
  • Increase in permeability or penetration may also be reflected by an increased ratio of molecules which pass through compared to those which are retarded, or alternatively, as compared to those which are applied.
  • This ratio, N may be increased by 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% 90% or 100% or more with the methods and compositions as described here.
  • Measurement of epidermal barrier function may be done in various ways.
  • the level or degree of penetration of an agent or composition can be determined by techniques known to those of skill in the art. For example, radiolabeling of an active compound or a tracer compound, followed by measurement of the amount of radiolabeUed compound absorbed by the skin enables one of skill in the art to determine levels of the composition absorbed using any of several methods of determining skin penetration of the test compound. Measurement of the amount of radiolabeUed compound which crosses the sl n layer may also be made.
  • a Franz chamber and cadaver system (also known as a Franz chamber penetration system) is used to measure penetration of an agent.
  • This system measures barrier function by allowing the measurement of amount of radiolabeUed compound which passes through a piece of sldn to a receptacle fluid.
  • the Franz chamber has the advantage in that it is a robust, quick and easy system, and is described in more detail below.
  • the methods and compositions described here are used to effect delivery of a drug or agent which is substantiaUy incapable of traversing the epidermal barrier of an untreated epidermis.
  • a drug or agent may have a molecular weight, hydrophobicity, conformation or shape etc which is incompatible with movement or diffusion across an untreated epidermal barrier.
  • Use of the methods and compositions described here enables such a drug or agent to cross the epidermal barrier of a treated epidermis.
  • the molecular weight cut-off of normal skin is in the region of about 1000 daltons.
  • the methods and compositions described here preferably enable the passage through the epidermal barrier of molecules of molecular weight of 1000 daltons or higher.
  • the methods and compositions described here enable the passage through the epidermal barrier, of molecules of 2 kDa or higher, such as molecules of 3 kDa, 4 kDa, 5kDa, lOkDa, 100 l Da, 1000 kDa, 10,000 l Da, 100,000 kDa or higher.
  • any molecule of or higher than the relevant modified molecular weight cut-off of the treated skin may be dehvered.
  • the molecular weight of any molecular may readily be determined by means known in the art.
  • searches may be made on suitable databases to identify molecules of specified molecular mass, to ascertain whether they are capable of being delivered to skin treated by the methods and compositions described here.
  • the epidermal barrier function may be reduced to match the molecular weight of the molecule to be dehvered.
  • the molecular weight cut-off may be modified according to the molecular weight of the molecule in question.
  • the desired degree of reduction of the epidermal barrier, and therefore the increase in penetration or permeability may be achieved by various ways.
  • the concentration of the or each degradative agent may be altered, reduced or increased to achieve the desired reduction in epidermal barrier function.
  • the degradative agent may be modified, chemicaUy or by molecular biology techniques to alter the activity of the agent. For example, a protease or lipase may be mutated to modulate the protease or lipase activity.
  • the time of application of the degradative agent may also be changed. Exposure for shorter periods will enable less reduction in epidermal barrier function than exposure for longer periods.
  • the reduction in epidermal barrier ftinction may be monitored to determine the optimal time of contact.
  • different degradative agents may be chosen based on their ability to cleave or degrade different components, and their efficiency of doing so.
  • different proteases may be chosen based on their abiUty to cleave or degrade different components, and their efficiency of doing so.
  • two or more proteases may be employed.
  • Each protease may be capable of degrading a different proteinaceous component of the barrier.
  • a protease capable of degrading corneodesmosin may be combined with a protease capable of degrading desmoglein, for example.
  • proteases capable of degrading corneodesmosin capable of degrading corneodesmosin, proteases capable of degrading corneodesmosin, proteases capable of degrading desmocollin, proteases capable of degrading desmoplaldn I, proteases capable of degrading desmoplaldn ⁇ , proteases capable of degrading plakoglobin (PG) and proteases capable of degrading plakophilin (PP) may be employed.
  • PG proteases capable of degrading plakoglobin
  • PP proteases capable of degrading plakophilin
  • a protease may be combined with a lipase to enable the reduction of both proteinaceous and Upidic components to enable increased reduction in barrier function.
  • the epidermal barrier function is reduced to enable the passage of a molecule of interest, such as a drug, through the epidermal barrier.
  • the epidermal barrier function is reduced to enable the accumulation or deUvery of a therapeuticaUy effective amount of a drag to the individual.
  • the epidermal barrier function is preferably reduced only to such an extent as to enable such passage, but not reduced enough to enable passage of molecules of substantiaUy higher molecular weight than the molecule of interest.
  • the reduced epidermal barrier function does not enable the passage of high molecular weight toxins or microorganisms such as bacterial or viruses.
  • the breakdown or reduction of the epidermal barrier is not permanent.
  • the epidermal barrier is broken down or reduced for long enough for a desired amount of the relevant molecule to be dehvered to pass through for delivery. More preferably, the epidermal barrier is broken down for only such a period, and restored subsequently. Restoration may be achieved by physical removal of the agent, such as by washing with oil or water based solutions, or by physical or chemical inactivation of the agent.
  • a protease is involved, for example, a peptide comprising a cleavage site may be used to neutraUse or reduce the activity of the protease.
  • a protease inhibitor may be applied to reduce or remove the protease activity.
  • the agent or drag may be derivatised to increase or decrease its abiUty to penetrate the epidermal barrier may be employed.
  • derivatisation may alter the hydrophobicity of the drug, its hydrophilicity or both.
  • Other agents or factors which are known to regulate epidermal cell-cell adhesion may be employed in conjunction with the agents described in this document.
  • Such other agents and/or factors include molecules capable of modulating calcium levels, for example, chelators, particularly chelators of divalent ions such as EDTA or EGTA. Glycosidases may also be employed.
  • Impaired desquamation of corneocytes is characteristic of a number of diseases such as psoriasis, acne vulgaris, ichthyosis and keratinosis pUaris, among others.
  • psoriasis impaired desquamation of corneocytes causes an increased thickness of the stratum comeum and the barrier is usuaUy enhanced.
  • the ability of the a molecule to penetrate the epidermal barrier may differ between individual to individual, depending on their disease state, and the term "epidermal barrier function" should be preferably taken to be refer to the barrier function of the specific individual in question.
  • the epidermal barrier may comprise for example one or more proteinaceous components; the methods and compositions as described here may therefore involve the degradation of one or more proteinaceous components comprised in the epidermal barrier.
  • the proteinaceous component comprises an adhesion protein, as described in further detail below.
  • adhesion protein we mean any protein which is involved in ceU-ceU adhesion.
  • the adhesion protein mediates ceU-ceU interaction between epitheUal ceUs, i.e., the adhesion protein is an epitheUal ceU adhesion protein. More preferably, the adhesion protein mediates ceU-ceU adhesion between corneocytes. Most preferably, the adhesion protein is a desmosomal protein or a corneodesmosomal protein.
  • the adhesion protein may suitably comprise any one or more of corneodesmosin, desmoglein, desmocollin, desmoplaldn I, desmoplaldn ⁇ , plakoglobin (PG) and plakoph in (PP).
  • Other adhesion proteins suitable for use in the methods and compositions described here are set out in Annex A, Table Al .
  • the barrier function may be performed by the stratum comeum.
  • the strength of the barrier function is dependent on strong adhesion between corneocytes (Egelrud, 2000). Accordingly, the effectiveness of the barrier function or epidermal barrier function may be directly proportional to the integrity of the stratum comeum, and in particular, the degree or level of adhesion between corneocytes of the stratum comeum.
  • the component of an epidermal barrier which is degraded according to the methods and compositions described here comprises a component of a desmosome or comeodesmosome, preferably a proteinaceous component.
  • a component of a desmosome or comeodesmosome preferably a proteinaceous component.
  • such an agent is capable of decreasing the ceU-ceU adhesion mediated by a comeodesmosome.
  • Comeodesmosomes also known as desmosomes
  • the desmosomes mediate the adhesion between keratinocytes.
  • the number of comeodesmosomes (desmosomes in upper layers of the epidermis) is increased in the stratum comeum.
  • Immunoelectron microscopy has been used to show the define the interactions within comeodesmosomes between proteins of the extraceUular core domain such as desmoglein and desmocollins and intraceUular comeodesmosomal proteins including desmoplaldns I and ⁇ , plakoglobin (PG) and plakophilins (PP) (Cowin and Burke, 1996).
  • the component of an epidermal barrier comprises an intraceUular comeodesmosomal protein, for example, desmoglein, desmocoUin, desmoplaldn I, desmoplaldn ⁇ , plakoglobin (PG) and plakophilin (PP).
  • the methods and compositions described here may comprise degradation of one or more of the foregoing, simultaneously or sequentiaUy, by the use of one or more agents.
  • the component of an epidermal barrier comprises a glycoprotein.
  • the component comprises corneodesmosin.
  • Three forms of the corneodesmosin with different weights 33-36 to 40-46 and 52-56 kDa have been isolated from the epidermis (Simon et al, 1997).
  • the methods and compositions described here therefore include treatment of an epidermis to degrade any one or more of the forms of corneodesmosin, optionaUy in combination with degradation of any one or more components of the epidermal barrier.
  • comeodesmosomal proteins in epidermal integrity is demonstrated by inherited disorders such as striate subtype of palmoplantar keratoderma caused by desmoplaldn haploinsufficiency (Armstrong et al, 1999). Mutations in loricrin gene lead to keratoderma of Camisa. LIPID COMPONENTS OF THE EPIDERMAL BARRIER
  • the Upid is secreted into lameUar bodies in the stratum granulosum (EUas 1983). At the interface between the stratum granulosum and stratum comeum, the Upids are extracted from the granular ceUs into the intercorneoctye space.
  • the Upids are then organised into highly organised multimeUar bUayer structures (Landmann 1988).
  • the stratum comeum can be visuaUsed rather tike a brick waU with the corneocytes forming the bricks and the lameUar Upids the mortar (EUas 1983).
  • Corneocytes contain a water retaining substance, natural moisturising factor (NMF), which retains water within them.
  • NMF natural moisturising factor
  • the high water content causes the corneocytes to sweU, preventing the formation of fissures and cracks between them.
  • the pliabiUty and elasticity of the skin is directly related to its water content. Normal healthy stratum comeum has comparatively high water content.
  • the epidermal barrier may therefore comprise for example one or more Upid components; the methods and compositions as described here may therefore involve the degradation of one or more tipidic components comprised in the epidermal barrier.
  • the methods and compositions described here employ Upases, by which term we mean any agent which is capable of degrading, destroying or cleaving a Upid, in particular, a Upid component of an epidermal barrier.
  • Corneodesmosin is an adhesion protein which is found in the stratum comeum, particularly in the comeodesmosomes.
  • a corneodesmosin sequence is set out in WO0162788.
  • the term "corneodesmosin” includes any variant or mutation of the corneodesmosin gene or protein, including variants associated with susceptibility to disease (for example as described in Guerrin et al., 2001, Tissue Antigens;57(l):32-8).
  • corneodesmosin genes amino acid sequences and nucleotide sequences
  • NT_007592 Homo sapiens chromosome 6 working draft sequence segment gi
  • XM_041759 Homo sapiens corneodesmosin (CDSN), mRNA gi
  • XM_004564 Homo sapiens corneodesmosin (CDSN), mRNA gijl 1419124
  • AJ238467 Homo sapiens CDSN gene, partial, haplotype HLA B8-Cw*0701; gi
  • AJ238465 Homo sapiens CDSN gene, partial, haplotype HLA B18-Cw*0701 gi
  • AJ238463 Homo sapiens CDSN gene, partial, haplotype HLA B57-Cw*0602,B37-Cw*0602 gi
  • CDSN corneodesmosin
  • CDSN gene
  • CDSN-2.23 aUele, partial cds gi
  • CDSN gene, CDSN-2.22 allele, partial cds gi
  • CDSN corneodesmosin
  • CDSN gene, CDSN- 1.52 allele, partial cds gi
  • CDSN Homo sapiens corneodesmosin
  • CDSN corneodesmosin
  • CDSN corneodesmosin
  • CDSN CDSN gene
  • CDSN- 1.11 allele CDSN- 1.11 allele, partial cds gi
  • the methods and compositions described here involve the regulation of proteolysis of an adhesion protein comprised in the epidermal barrier, to enable transdermal deUvery of a molecule.
  • the methods and compositions described here involve the regulating (preferably up-regulating) the activity of an endogenous protease which degrades a component of the epidermal barrier of an individual.
  • endogenous proteases include Stratum Comeum Chymotryptic Enzyme (SCCE; kallikrein 7, KLK7), Stratum Comeum Tryptic Enzyme (SCTE; kallUcrein 5, KLK5), KLKl, KLK2, KLK3 and KLK4.
  • SCCE Stratum Comeum Chymotryptic Enzyme
  • SCTE kallUcrein 5, KLK5
  • KLKl KLK2, KLK3 and KLK4
  • endogenous proteases may be applied to the sldn using the methods and compositions described here, to supplement the activity of he protease in the skin. Endogenous proteases are referred to here as "primary" proteases.
  • endogenous proteases relate to their allogenicity. Use of endogenous proteases is less likely to provoke an inappropriate immune response to cause for example inflammation. Endogenous proteases are also generaUy more specific in their activity, in that they are only capable of degrading certain substrates. Accordingly, use of endogenous proteases wiU avoid degradation of other components of the skin, for example, components of the sldn that do not contribute to the strength or integrity of the epidermal barrier.
  • an agent is employed which is capable of achieving this.
  • Such an agent may comprise a molecule, such as a transcription factor, capable of increasing the quantity, activity and/or bio-avaUabiUty of a protease responsible for break down of an adhesion protein.
  • the methods and compositions as described here may further involve up-regulating the expression and/or activity of a protease responsible for breaking down an adhesion protein.
  • the transcription and/or translation of such a protease may be up-regulated as a means to enable breakdown of a proteinaceous component of the epidermal barrier to enable transdermal deUvery of a molecule.
  • Suitable proteases the expression of which may be regulated include SCCE and SCTE, described in detaU elsewhere.
  • an agent comprising a molecule which up-regulates protease activity may be used in the methods and compositions described here.
  • the protease whose activity, expression, bioava abitity, etc is upregulated need not be one which is normaUy involved in the proteolysis of the epidermal barrier component.
  • the methods and compositions described here include the administration of any protease to the individual, so long as such administration is capable of degrading a component of an epidermal barrier to enable transdermal deUvery of a drag or agent.
  • Such a protease is referred to here as a "secondary protease”.
  • suitable secondary proteases include aminopeptidase M, carboxypeptidase
  • P carboxypeptidase Y, caspase 1,4,5, caspase 2,3,7, caspase 6,8,9, chymotrypsin, Factor Xa, pepsin, TEN, thrombin or trypsin may therefore be employed.
  • Regulation of proteolysis may also be achieved through regulation of activities of molecules involved in regulating protease activity.
  • a protease inhibitor which is capable of inhibiting a protease activity capable of breakdown of an adhesion protein may be down- regulated as a means to effect transdermal deUvery of an agent.
  • the protease inhibitor whose expression and/or activity is down-regulated preferably comprises a natural protease inhibitor which physiologicaUy inhibits the protease in question (i.e., the protease responsible for proteolysis of the adhesion protein).
  • Down-regulation of protease inhibitor may be achieved by deactivation or repression of transcription and/or translation of the protease inhibitor to increase the activity of proteases.
  • Preferred protease inhibitors include for example, SKALP and SLPI, wh e preferred proteases include SCCE and SCTE.
  • Expression of the protease inhibitor may be effected at the transcriptional and/or the translational level.
  • a protease may be administered in combination with an agent which down-regulates a protease inhibitor.
  • an agent such as a protease may be formulated in an emoUient base.
  • the protease or other agent wUl effect the degradation of an epidermal barrier component (such as an adhesion protein, for example corneodesmosin).
  • an epidermal barrier component such as an adhesion protein, for example corneodesmosin.
  • the epidermal barrier is compromised; in particular, the cohesion between corneocytes is reduced, allowing transport of a relevant agent or drug across the epidermal barrier.
  • Expression of one or more genes coding for a protease may be used to increase protease activity.
  • expression vectors which express, for example, SCCE, SCTE, aminopeptidase M, carboxypeptidase P, carboxypeptidase Y, caspase 1,4,5, caspase 2,3,7, caspase 6,8,9, chymotrypsin, Factor Xa, pepsin, TEN, thrombin or trypsin, or other proteases in order to increase protease activity to effect proteolysis of the adhesion protein.
  • endogenous production of primary proteases may be enhanced by up-regulating transcription and/or translation of the relevant protease genes, by means known in the art.
  • a preferred agent for use in the methods and compositions described here comprises any protease capable of effecting the degradation of a component of an epidermal barrier, preferably an adhesion protein.
  • proteases which may be used in the methods and compositions described here include the foUowing:
  • SCCE Stratum Comeum Chymotryptic Enzyme
  • SCTE Stratum Comeum Tryptic Enzyme
  • SCCE stratum comeum chymotryptic enzyme
  • KLK7 stratum comeum tryptic enzyme
  • SCTE stratum comeum tryptic enzyme
  • KLK5 stratum comeum tryptic enzyme 5
  • SCCE and SCTE are transported to the stratum comeum extraceUular space during comification.
  • SCCE is produced as an inactive precursor and there is a need for an activating enzyme to confer to SCCE its proteolytic activity.
  • SCTE is thought to be the enzyme involved in SCCE activation.
  • a cluster of kallikrein genes including SCCE and SCTE has been mapped in chromosome 19ql3.3-13.4. This includes at least 6 structuraUy and evolutionary- related members (KLKl, KLK2, KLK3, KLK4, SCCE and SCTE).
  • KLK7 and SCTE KLK-L2 are mainly expressed in skin. They are also expressed in other tissues such as brain, kidney, mammary and saUvary glands (Yousef et al, 2000; Yousef and Diamandis, 1999).
  • homologues of adhesion proteins, proteases and protease inhibitors are also useful for the methods and compositions described here.
  • skin specific proteases such as SCCE may be identified by conventional screening or database homology searching.
  • SCCE homologues may also be used in the methods and compositions described here.
  • protease inhibitors whose activity may be down-regulated include any of the protease inhibitors set out in Annex A, Table A3. Particularly preferred examples of protease inhibitors include the Mowing:
  • PI3 or SKALP is another serine protease inhibitor produced by keratinocytes. It is over-expressed in the subcomeal layers of lesional psoriatic sldn and in other skin disorders such as Behcet's syndrome, Sweet's syndrome, pyoderma gangrenosum, urticaria and cutaneous aUergic vasculitis (Tanaka et al. 2000). Changes of SKALP expression are capable of affecting SCCE and SCTE activities and hence disturb the structure of superficial layers of the epidermis in skin disorders such as psoriasis and eczema.
  • Mutants, variants, etc of the adhesion proteins, proteases, and protease inhibitors etc are encompassed by the invention. Such mutants include deletions, transversions, transitions, nucleic acid substitutions, amino acid substitutions (preferably with conserved residues), insertions, etc.
  • compositions of our invention rely, in some embodiments, on blocking the activity of protease inhibitors, or blocldng the activity of inhibitors of Upase activity, or both. They may further employ in some embodiments agents capable of increasing the activity of a protease and/or Upase. Agents which are capable of increasing the activity of a protease are referred to as agonists of that activity. Similarly, antagonists reduce the activity of a protease inhibitor.
  • antagonists reduce the activity of a protease inhibitor.
  • antagonist as used in the art, is generaUy taken to refer to a compound which binds to an enzyme and inhibits the activity of the enzyme.
  • the term as used here, however, is intended to refer broadly to any agent which inhibits the activity of a molecule, not necessarily by binding to it. Accordingly, it includes agents which affect the expression of a protein such as a protease inhibitor, or the biosynthesis of a molecule such as a protease inhibitor, or the expression of modulators of the activity of the protease or protease inhibitor.
  • the specific activity which is inhibited may be any activity which is characteristic of the enzyme or molecule, for example, protease activity or protease inhibitor activity. Assays for protease activity and protease inhibitor activity are known in the art.
  • the antagonist may bind to and compete for one or more sites on the relevant molecule, for example, a protease enzyme, preferably, the catalytic site of the protease enzyme. Preferably, such binding blocks the interaction between the molecule and another entity (for example, the interaction between a protease enzyme and its substrate, for example, an adhesion molecule).
  • the antagonist need not necessarily bind directly to a catalytic site, and may bind for example to an adjacent site, another protein (for example, a protein which is complexed with the enzyme) or other entity on or in the ceU, so long as its binding reduces the activity of the enzyme or molecule.
  • an antagonist may include a substrate of the enzyme, or a fragment of this which is capable of binding to the enzyme.
  • whole or fragments of a substrate generated natively or by peptide synthesis may be used to compete with the substrate for binding sites on the enzyme.
  • an immunoglobulin for example, a monoclonal or polyclonal antibody
  • the antagonist may also include a peptide or other smaU molecule which is capable of interfering with the binding interaction.
  • Other examples of antagonists are set forth in greater detaU below, and wiU also be apparent to the skilled person.
  • Blocking the activity of a protease or protease inhibitor may also be achieved by reducing the level of expression of the protease or inhibitor in the ceU.
  • the cell may be treated with antisense compounds, for example oligonucleotides having sequences specific to the protease or protease inhibitor mRNA.
  • the antagonist or agent may itself be a protease which cleaves the protease or protease inhibitor.
  • proteases include aminopeptidase M, carboxypeptidase P, carboxypeptidase Y, caspase 1,4,5, caspase 2,3,7, caspase 6,8,9, chymotrypsin, Factor Xa, pepsin, TEN, thrombin, trypsin etc.
  • An agent of use in the methods and compositions described here is one which is capable of reducing epidermal barrier function, for example, by degrading a component of the epidermal barrier.
  • the term "agenf includes but is not limited to agents such as an atom or molecule, wherein a molecule may be inorganic or organic, a biological effector molecule and/or a nucleic acid encoding an agent such as a biological effector molecule, a protein, a polypeptide, a peptide, a nucleic acid, a peptide nucleic acid (PNA), a virus, a virus-tike particle, a nucleotide, a ribonucleotide, a synthetic analogue of a nucleotide, a synthetic analogue of a ribonucleotide, a modified nucleotide, a modified ribonucleotide, an amino acid, an amino acid analogue, a modified amino acid, a modified amino acid analogue, a steroid, a proteoglycan, a Upid, a fatty acid
  • antagonists are also intended to include, a protein, polypeptide or peptide including, but not limited to, a structural protein, an enzyme, a cytokine (such as an interferon and/or an interleuldn) an antibiotic, a polyclonal or monoclonal antibody, or an effective part thereof, such as an Fv fragment, which antibody or part thereof may be natural, synthetic or humanised, a peptide hormone, a receptor, a signalling molecule or other protein; a nucleic acid, as defined below, including, but not limited to, an oUgonucleotide or modified oUgonucleotide, an antisense oUgonucleotide or modified antisense oUgonucleotide, cDNA, genomic DNA, an artificial or natural chromosome (e.g.
  • RNA including mRNA, tRNA, rRNA or a ribozyme, or a peptide nucleic acid (PNA); a virus or viras- like particles; a nucleotide or ribonucleotide or synthetic analogue thereof, which may be modified or unmodified; an amino acid or analogue thereof, which may be modified or unmodified; a non-peptide (e.g., steroid) hormone; a proteoglycan; a lipid; or a carbohydrate.
  • PNA peptide nucleic acid
  • SmaU molecules including inorganic and organic chemicals, which bind to and occupy the active site of the polypeptide thereby making the catalytic site inaccessible to substrate such that normal biological activity is prevented, are also included.
  • small molecules include but are not limited to small peptides or peptide-tike molecules.
  • any molecule may be delivered according to the methods and compositions described here.
  • Such a molecule to be deUvered may take the form of any of the entities as specified above for agents.
  • the molecules to be deUvered preferably comprise therapeutic compounds such as drugs.
  • the methods and compositions described here are also suitable for the deUvery of compounds having a cosmetic function.
  • the antagonist may comprise one or more antisense compounds, including antisense RNA and antisense DNA, which are capable of reducing the level of expression of a protease inhibitor and thereby increasing protease activity, preferably endogenous protease activity.
  • the antisense compounds comprise sequences complementary to the mRNA encoding the protease inhibitor.
  • the antisense compounds are otigomeric antisense compounds, particularly oUgonucleotides.
  • the antisense compounds preferably specifically hybridize with one or more nucleic acids encoding the protease inhibitor.
  • nucleic acid encoding protease or encompasses DNA encoding the protease, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA.
  • the specific hybridization of an otigomeric compound with its target nucleic acid interferes with the normal ftinction of the nucleic acid.
  • RNA to be interfered with may include aU vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, spUcing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or faciUtated by the RNA.
  • the overall effect of such interference with target nucleic acid function is modulation of the expression of the protease inhibitor.
  • Antisense constructs are described in detail in US 6,100,090 (Monia et al), and Neckers et al, 1992, Crit Rev Oncog 3(1-2):175-231, the teachings of which document are specifically incorporated by reference.
  • modulation means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene.
  • the expression of a gene encoding a protease may be increased, or the expression of a gene encoding an inhibitor of protease inhibitor activity may be decreased, or both.
  • inhibition of expression in particular, inhibition of expression of protease inhibitor, is the preferred form of modulation of gene expression and mRNA is a preferred target.
  • the methods and compositions described here are useful for enabling transdermal deUvery of a molecule across the skin of an individual suffering from a disease associated with increased ceU-ceU adhesion of epithelial ceUs, in particular corneocytes. Increased adhesion results in an increased thickness of the stratum comeum, and increased barrier function.
  • a disease associated with increased ceU-ceU adhesion of epithelial ceUs, in particular corneocytes Increased adhesion results in an increased thickness of the stratum comeum, and increased barrier function.
  • Such diseases are referred to in this document as Group 2 diseases.
  • Group 2 diseases include psoriasis, the ichtyoses, acne vulgaris and keratoses pilaris.
  • the skin of such diseased individuals provides more resistance to drug penetration than normal undiseased skin.
  • the methods and compositions described here enable the epidermal barrier of such diseased sldn to be reduced to allow passage and delivery of a molecule such as a drag.
  • the molecule or drug may be one which is intended to reUeve or treat the condition leading to the increased barrier ftinction, i.e., the Group 2 disease, but need not be.
  • the sldn of a Group 2 patient such as a psoriatic individual
  • a normal undiseased skin is typically in the region of 1000 Daltons
  • a psoriatic sldn is substantiaUy incapable of aUowing passage of molecules above about 800 Da. Therefore, in a particular embodiment, the methods and compositions described here are used to enable delivery of molecules such as drags above about 800 Da in molecular weight across the sldn of a Group 2 individual.
  • the molecule to be deUvered comprises ascomycin or tacrolimus.
  • ceU-ceU adhesion in Group 2 sldn is stronger than in normal sldn, the amount or activity of agent appUed to effect degradation of an adhesion protein or lipid may need to be increased.
  • compositions and methods of our invention are suitable for assisting or enabling the deUvery of drugs or other agents across psoriatic sldn. They are therefore useful for drug deUvery to psoriatic individuals.
  • Psoriasis manifests itself as inflamed swoUen skin lesions covered with silvery white scale. Characteristics of psoriasis include pus-like bUsters (pustular psoriasis), severe sloughing of the skin (erythrodermic psoriasis), drop-tike dots (guttate psoriasis) and smooth inflamed lesions (inverse psoriasis).
  • psoriasis The causes of psoriasis are currently unknown, although it has been estabUshed as an autoimmune sldn disorder with a genetic component.
  • One in three people report a family history of psoriasis, but there is no pattern of inheritance. However, there are many cases in which children with no apparent famUy history of the disease wiU develop psoriasis.
  • Whether a person actuaUy develops psoriasis may depend on "trigger factors" which include systemic infections such as strep throat, injury to the sldn (the Koebner phenomenon), vaccinations, certain medications, and intramuscular injections or oral steroid medications. Once something triggers a person's genetic tendency to develop psoriasis, it is thought that in turn, the immune system triggers the excessive skin ceU reproduction.
  • Sldn cells are programmed to foUow two possible programs: normal growth or wound healing.
  • normal growth sldn ceUs are created in the basal ceU layer, and then move up through the epidermis to the stratum comeum, the outermost layer of the sldn. This normal process takes about 28 days from cell birth to death.
  • a wound healing program regenerative maturation
  • ceUs are produced at a much faster rate, the blood supply increases and localized inflammation occurs.
  • Lesional psoriasis is characterized by ceU growth in the alternate growth program.
  • Sldn cells (Iceratinocytes) switch from the normal growth program to regenerative maturation, ceUs are created and pushed to the surface in as Uttle as 2-4 days, and the sldn cannot shed the ceUs fast enough.
  • the white scale (“plaque”) that usuaUy covers the lesion is composed of dead skin cells, and the redness of the lesion is caused by increased blood supply to the area of rapidly dividing slcin ceUs.
  • Psoriasis is a geneticaUy determined disease of the skin characterized by two biological hallmarks. First, there is a profound epidermal hyperproliferation related to accelerated and incomplete differentiation. Second, there is a marked inflammation of both epidermis and dermis with an increased recruitment of T lymphocytes, and in some cases, formation of neutrophU microabcesses. Many pathologic features of psoriasis can be attributed to alterations in the growth and maturation of epidermal keratinocytes, with increased proUferation of epidermal ceUs, occurring within 0.2 mm of the skin's surface. Traditional investigations into the pathogenesis of psoriasis have focused on the increased proUferation and hyperplasia of the epidermis.
  • the time for a ceU to move from the basal layer through the granular layer is 4 to 5 weeks.
  • the time is decreased sevenfold to tenfold because of a shortened ceU cycle time, an increase in the absolute number of ceUs capable of proUferating, and an increased proportion of ceUs that are actuaUy dividing.
  • the hyperproUferative phenomenon is also expressed, although to a substantiaUy smaUer degree, in the cUnicaUy uninvolved skin of psoriatic individuals.
  • a common form of psoriasis psoriasis vulgaris, is characterized by weU-demarcated erythematous plaques covered by thick, silvery scales.
  • a characteristic finding is the isomorphic response (Koebner phenomenon), in which new psoriatic lesions arise at sites of cutaneous trauma.
  • guttate psoriasis a form of the disease that often erupts foUowing streptococcal pharyngitis
  • pustular psoriasis which is characterized by numerous sterile pustules, often 2 to 5 mm in diameter, on the palms and soles or distributed over the body.
  • Objective methods which are employed for establishing the effect of treatment of psoriasis individuals include the resolution of plaques by visual monitoring and with photography. The visual scoring is done using PASI (Psoriasis Area and Severity Index) score (see Fredericksson, A J, Peterssonn B C Dermatologies 157:238-244 (1978)). Psoriasis affects approximately 2% of the UK population and may be associated with arthritis (in 7-25%) and Crohn's disease. The effect upon the individual self confidence and social activity can be catastrophic. Currently therapies for psoriasis are only suppressive and systemic treatments have significant adverse effects.
  • PASI Psoriasis Area and Severity Index
  • MHC S gene corneodesmosin
  • HLA-C histocompatibiUty region
  • compositions described here are also suitable for effecting, assisting or enabling the deUvery of drugs or other agents
  • Compositions described here are useful for enabling transdermal deUvery of a molecule across the skin of an individual suffering from a disease associated with decreased ceU-ceU adhesion of epitheUal ceUs, in particular corneocytes. Such diseases are referred to in this document as Group 1 diseases. Decreased adhesion results in a decreased thickness of the stratum comeum.
  • Group 1 diseases are characterised by impaired barrier ftinction. It wUl be appreciated that within such diseases, penetration of molecules or drags to be delivered is already greater compared to normal, undiseased, skin.
  • the methods and compositions described here are however useful if such impaired barrier function associated with the Group I disease is insufficient to enable deUvery of a desired amount of drug to the individual. Accordingly, the methods and compositions described here are particularly useful for deUvery of drugs and other therapeutic molecules in for example mUd forms of Group I diseases, such as atopic eczema.
  • a first subgroup of Group 1 diseases (Subgroup 1.1) is characterised by an impaired barrier which permits more penetration of an irritant, aUergen or other xenobiotic compared to normal undiseased skin. Examples of such diseases affecting the skin include atopic eczema, sebarrhoeic eczema, irritant contact dermatitis, and aUergic contact dermatitis.
  • a second subgroup of Group 1 diseases (Subgroup 1.2) is characterised by an impaired barrier that permits more penetration of bacteria, virus, other micro-organisms or micro-organism products e.g. superantigenic exotoxin, compared to normal undiseased skin.
  • a third subgroup of Group 1 diseases (Subgroup 1.3) is characterised by an impaired barrier that permits more penetration of a carcinogen compared to normal undiseased sldn.
  • diseases affecting the skin include melanoma, squamous ceU carcinoma, basal cell carcinoma, cutaneous lymphoma, and other skin cancers.
  • diseases affecting the bowel include matignancies of the entire gastrointestinal tract. Lung malignancies are examples of diseases affecting the lung.
  • Desmosomes are symmetrical structures that form disc-shaped interceUular junctions between epitheUal ceUs. In the epidermis the desmosomes mediate the adhesion between keratinocytes. In psoriasis, various ichtyoses and sldn xerosis, the number of comeodesmosomes (desmosomes in upper layers of the epidermis) is increased in the stratum comeum.
  • Corneodesmosin is a glycoprotein of comeodesmosomes. Three forms of the corneodesmosin with different weights 33-36 to 40-46 and 52-56 kDa have been isolated from the epidermis (Simon et al, 1997). Mutations within the corneodesmosin/S gene and related genes within the MHC epidermal gene cluster (chromosome 6p21) result in a reduced cohesion between corneocytes.
  • the methods and compositions described here may employ an antibody against a protease inhibitor, to down-regulate its activity, and to enable degradation of a component of an epidermal barrier.
  • the antibody may be polyclonal or monoclonal, and may be capable of specifically binding to epitopes on the protease inhibitor.
  • the protease inhibitor in preparing the antibody, may be used as a source of the immunogen.
  • Peptide amino acid sequences isolated from the amino acid sequence of the protease inhibitor may also be used as an immunogen.
  • antibodies may be generated against the protease inhibitors Antileukoprotease and Elafin Protease Inhibitor 3, by immunisation with the whole proteins, a fragment of the protein, or a peptide derived or synthesised from the protein.
  • the antibodies may be prepared against a synthetic peptide based on the sequence, or prepared recombinantly by cloning techniques or the natural gene product and/or portions thereof may be isolated and used as the immunogen.
  • proteins or peptides may be used to produce antibodies by standard antibody production technology weU known to those sldUed in the art as described generaUy in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1988.
  • a host such as a rabbit or goat, is immunized with the protein or peptide, generaUy with an adjuvant and, if necessary, coupled to a carrier; antibodies to the protein are coUected from the sera.
  • the technique involves hyperimmunization of an appropriate donor, generaUy a mouse, -with the protein or peptide fragment and isolation of splenic antibody producing ceUs. These ceUs are fused to a ceU having immortaUty, such as a myeloma ceU, to provide a fused ceU hybrid which has immortaUty and secretes the required antibody. The ceUs are then cultured, in bulk, and the monoclonal antibodies harvested from the culture media for use.
  • the antibody may be bound to a soUd support substrate or conjugated with a detectable moiety or be both bound and conjugated as is well known in the art. (For a general discussion of conjugation of fluorescent or enzymatic moieties see Johnstone and Thorpe, Immunochemistry in Practice, BlackweU Scientific Publications, Oxford, 1982.) The binding of antibodies to a solid support substrate is also well known in the art.
  • the detectable moieties contemplated with the present invention may include, but are not limited to, fluorescent, metalUc, enzymatic and radioactive markers such as biotin, gold, ferritin, alkaline phosphatase, ⁇ -galactosidase, peroxidase, urease, fluorescein, rhodamine, tritium, 14 C and iodination.
  • Nucleic acids useful in the methods and compositions described here include antisense molecules which are capable of binding to and down-regulating the level or expression or activity of a protease inhibitor or lipase inhibitor. Furthermore, expression of the adhesion protein may also be downregulated by the use of an appropriate antisense nucleic acid against an adhesion protein, for example, an antisense RNA to corneodesmosin, or a fragment of corneodesmosin.
  • Protease activity or Upase activity may be upregulated by increasing the expression of protease or Upase.
  • a nucleic acid sequence encoding the protease and/or lipase, suitably linked to a promoter may be introduced to the skin of an individual; expression of the protease or Upase enables or assists degradation of the appropriate components of the epidermal barrier.
  • the term "nucleic acid” is defined to encompass DNA and RNA or both synthetic and natural origin which DNA or RNA may contain modified or unmodified deoxy- or dideoxy- nucleotides or ribonucleotides or analogues thereof.
  • the nucleic acid may exist as single- or double-stranded DNA or RNA, an RNA/DNA heteroduplex or an RNA/DNA copolymer, wherein the term “copolymer” refers to a single nucleic acid strand that comprises both ribonucleotides and deoxyribonucleotides.
  • synthetic is defined as that which is produced by in vitro chemical or enzymatic synthesis.
  • Nucleic acid sequences useful according to the methods and compositions described her include those encoding adhesion proteins, as well as proteases, protease inhibitors, etc. They furthermore include sequences encoding nuclear proteins, cytoplasmic proteins, rnitochondrial proteins, secreted proteins, plasmalemma-associated proteins, serum proteins, viral antigens, bacterial antigens, protozoal antigens and parasitic antigens. Also included are sequences encoding proteins, lipoproteins, glycoproteins, phosphoproteins and nucleic acids (e.g., RNAs such as ribozymes or antisense nucleic acids).
  • RNAs such as ribozymes or antisense nucleic acids
  • Ribozymes of the hammerhead class are the smaUest known, and lend themselves both to in vitro synthesis and deUvery to cells (summarised by SuUivan, 1994, J. Invest. Dermatol., 103: 85S-98S; Usman et al., 1996, Curr. Opin. Struct. Biol., 6: 527-533).
  • vectors comprising an expression control sequence operatively linked to the nucleic acid sequence, for example, a nucleic acid sequence encoding a protease such as Stratum Comeum Chymotryptic Enzyme and Stratum Comeum Tryptic Enzyme, as weU as host ceUs, selected from suitable eukaryotic and prokaryotic ceUs, which are transformed with these vectors.
  • a protease such as Stratum Comeum Chymotryptic Enzyme and Stratum Comeum Tryptic Enzyme, as weU as host ceUs, selected from suitable eukaryotic and prokaryotic ceUs, which are transformed with these vectors.
  • Vectors are known or may be constructed by those sktiled in the art and should contain all expression elements necessary to achieve the desired transcription of the sequences. Other beneficial characteristics may also be contained within the vectors such as mechanisms for recovery of the nucleic acids in a different form.
  • Phagemids are a specific example of such beneficial vectors because they may be used either as plasmids or as bacteriophage vectors. Examples of other vectors include viruses such as bacteriophages, baculoviruses and retrovirases, DNA viruses, cosmids, plasmids and other recombination vectors.
  • the vectors may also contain elements for use in either procaryotic or eucaryotic host systems.
  • One of ordinary slciU in the art wiU know which host systems are compatible with a particular vector.
  • the vectors may be introduced into ceUs or tissues by any one of a variety of known methods within the art. Such methods may be found generaUy described in Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Springs Harbor Laboratory, New York (1992), in Ausubel et al., Current Protocols in Molecular Biology, John WUey and Sons, Baltimore, Md. (1989), Chang et al., Somatic Gene Therapy, CRC Press, Ann Arbor, Mich. (1995), Vega et al., Gene Targeting, CRC Press, Ann Arbor, Mich.
  • viruses are very specialized and typicaUy infect and propagate in specific ceU types. Thus, their natural specificity may be used to target the vectors to specific ceU types in vivo or within a tissue or mixed culture of ceUs. Viral vectors may also be modified with specific receptors or tigands to alter target specificity through receptor mediated events.
  • vectors containing antisense nucleic acids may be employed to express protein or antisense message to reduce the expression of the target nucleic acid and therefore its activity.
  • DNA viral vector for introducing and expressing antisense nucleic acids is the adenovirus derived vector Adenop53TK.
  • This vector expresses a herpes virus thymidine lcinase (TK) gene for either positive or negative selection and an expression cassette for desired recombinant sequences such as antisense sequences.
  • TK herpes virus thymidine lcinase
  • This vector may be used to infect ceUs that have an adenovirus receptor.
  • This vector as weU as others that exhibit similar desired functions may be used to treat a mixed population of ceUs include, for example, an in vitro or ex vivo culture of ceUs, a tissue or a human subject.
  • Additional features may be added to the vector to ensure its safety and/or enhance its therapeutic efficacy.
  • Such features include, for example, markers that may be used to negatively select against ceUs infected with the recombinant virus.
  • An example of such a negative selection marker is the TK gene described above that confers sensitivity to the anti-viral gancyclovir. Negative selection is therefore a means by which infection may be confroUed because it provides inducible suicide through the addition of antibiotic. Such protection ensures that if, for example, mutations arise that produce altered forms of the viral vector or sequence, cellular transformation wiU not occur.
  • Features that limit expression to particular cell types may also be included. Such features include, for example, promoter and regulatory elements that are specific for the desired ceU type.
  • Recombinant viral vectors are another example of vectors useful for in vivo expression of a desired nucleic acid because they offer advantages such as lateral infection and targeting specificity.
  • Lateral infection is inherent in the life cycle of, for example, retrovirus and is the process by which a single infected ceU produces many progeny virions that bud off and infect neighbouring ceUs. The result is that a large area becomes rapidly infected, most of which was not initiaUy infected by the original viral particles. This is in contrast to vertical-type of infection in which the infectious agent spreads only through daughter progeny.
  • Viral vectors may also be produced that are unable to spread laterally. This characteristic may be useful if the desired purpose is to introduce a specified gene into only a localized number of targeted cells.
  • viruses are very specialized infectious agents that have evolved, in many cases, to elude host defense mechanisms.
  • TypicaUy viruses infect and propagate in specific ceU types.
  • the targeting specificity of viral vectors utilizes its natural specificity to specificaUy target predetermined cell types and thereby introduce a recombinant gene into the infected ceU.
  • the vector to be used in the methods of the invention wiU depend on desired ceU type to be targeted. For example, a vector specific for epitheUal ceUs may be used for treatment of skin diseases. Likewise, if diseases or pathological conditions of the lung are to be treated, then a viral vector that is specific for lung ceUs and their precursors, preferably for the specific type of lung cell, should be used.
  • Retroviral vectors may be constructed to function either as infectious particles or to undergo only a single initial round of infection.
  • the genome of the vims is modified so that it maintains ati the necessary genes, regulatory sequences and packaging signals to synthesize new viral proteins and RNA. Once these molecules are synthesized, the host ceU packages the RNA into new viral particles which are capable of undergoing further rounds of infection.
  • the vector's genome is also engineered to encode and express the desired recombinant gene. In the case of non-infectious viral vectors, the vector genome is usuaUy mutated to destroy the viral packaging signal that is required to encapsulate the RNA into viral particles.
  • any particles that are formed wiU not contain a genome and therefore cannot proceed through subsequent rounds of infection.
  • the specific type of vector will depend upon the intended application.
  • the actual vectors are also known and readUy avaUable within the art or may be constructed by one skilled in the art using weU-known methodology.
  • the procedure may take advantage of their target specificity and consequently, do not have to be administered locaUy at the diseased site.
  • local administration may provide a quicker and more effective treatment, adierinistration may also be performed by, for example, intravenous or subcutaneous injection into the subject.
  • Injection of the viral vectors into a spinal fluid may also be used as a mode of administration, especiaUy in the case of neuro-degenerative diseases.
  • FoUowing injection the viral vectors wiU circulate until they recognize host ceUs with the appropriate target specificity for infection.
  • Transfection vehicles such as liposomes may also be used to introduce the non-viral vectors described above into recipient ceUs within the inoculated area. Such transfection vehicles are known by one skiUed within the art.
  • the agent capable of reducing an epidermal barrier function may be administered to an individual in a number of ways.
  • the agent is appUed to an individual in the form of a cream or emoUient.
  • the agent is administered or applied in the form of a patch comprising the agent.
  • more than one agent may be used, for example, a protease and a lipase, and that therefore the cream or emoUient or patch may comprise more than one agent capable of reducing an epidermal barrier function.
  • the creams may be used in conjunction with the patches.
  • a cream comprising an agent capable of reducing an epidermal barrier function may be appUed to the skin, foUowed by a patch containing the drug (optionaUy together with an agent capable of reducing an epidermal barrier function, which may be the same agent as in the cream, or a different agent).
  • agent for some applications, it is preferable to administer a long acting form of agent or composition using formulations known in the arts, such as polymers.
  • the agent can be incorporated into a dermal patch (Junginger, H. E., in Ada Pharmaceutica Nordica 4:117 (1992); Thacharodi et al, in Biomaterials 16:145-148 (1995); Niedner R., in Hautier 39:761- 766 (1988)) or a patch according to methods known in the art, to increase the efficiency of delivery of the drug to the areas to be treated.
  • a cream comprising the agent may be used together with a separate cream comprising the drug or molecule to be deUvered.
  • a cream may be supptied containing the agent or agents, together with one containing the drag or drugs.
  • a cream comprising an agent capable of reducing an epidermal barrier function for example a cream comprising a protease capable of degrading corneodesmosin, is suppUed for use with, or together with a cream comprising a drag or other molecule to be deUvered.
  • Two creams comprising two different agents may be suppUed with one containing the drag.
  • the cream containing the agent may be suppUed on its own, for use with pre-existing creams or other formulations comprising the drag to be deUvered, to enhance their deUvery.
  • the cream containing the agent wiU be administered to the individual and aUowed to act before administration of the cream containing the drug to be delivered.
  • the creams may be appUed simultaneously or sequentiaUy, or as mixtures with each other.
  • a first cream comprising an agent capable of reducing an epidermal barrier function is appUed to the individual before a cream comprising a drag or molecule to be deUvered.
  • the agent capable of reducing an epidermal barrier function is appUed for sufficient time to substantiaUy reduce epidermal barrier ftinction before the molecule or drug to be deUvered.
  • a first cream comprising the agent capable of reducing an epidermal barrier ftinction is administered substantially before a second cream comprising a molecule or drug to be delivered.
  • the cream or emoUient comprising the agent may further comprise the drug or molecule to be deUvered.
  • a single cream may be produced comprising one or more agents with one or more drugs.
  • cream should be taken to include reference to a Uquid, semi-Uquid, gel or sol preparation comprising the agent, optionaUy with other components, for example, an emoUient, a lotion, an ointment, a tincture, etc.
  • the cream may comprise semi-soUd and gel-Ulce vehicles that include a polymer thickener, water, preservatives, active surfactants or emulsifiers, antioxidants, sun screens, and a solvent or mixed solvent system.
  • U.S. Pat. No. 5,863,560 discusses a number of different combinations which can aid in the exposure of the sldn to a medicament.
  • the cream may comprise one or more carriers, which may include in any number or combination an aqueous Uquid, an alcohol base liquid, a water soluble gel, a lotion, an ointment, a nonaqueous Uquid base, a mineral oU base, a blend of mineral oil and petrolatum, lanolin, Uposomes, protein carriers such as serum albumin or gelatin, powdered cellulose carmel, and combinations thereof.
  • carriers may include in any number or combination an aqueous Uquid, an alcohol base liquid, a water soluble gel, a lotion, an ointment, a nonaqueous Uquid base, a mineral oU base, a blend of mineral oil and petrolatum, lanolin, Uposomes, protein carriers such as serum albumin or gelatin, powdered cellulose carmel, and combinations thereof.
  • the agent may also be incorporated into and administered in the form of a smear, spray, a Uquid absorbed wipe, and combinations thereof.
  • the cream may comprise a polymer thickener.
  • Polymer thickeners that may be used include those known to one skiUed in the art, such as hydrophiUc and hydroalcohoUc gelling agents frequently used in the cosmetic and pharmaceutical industries.
  • the hydrophiUc or hydroalcohoUc gelling agent comprises "CARBOPOL” (B. F. Goodrich, Cleveland, Ohio), "HYPAN” (Kingston Technologies, Dayton, N.J.), “NATROSOL” (Aqualon, Wilmington, Del.), “KLUCEL” (Aqualon, Wilmington, Del.), or “STABILEZE” (ISP Technologies, Wayne, N.J.).
  • the geUing agent comprises between about 0.2% to about 4% by weight of the composition. More particularly, the preferred compositional weight percent range for "CARBOPOL” is between about 0.5% to about 2%, while the preferred weight percent range for "NATROSOL” and “KLUCEL” is between about 0.5% to about 4%. The preferred compositional weight percent range for both "HYPAN” and “STABILEZE” is between about 0.5% to about 4%.
  • CARBOPOL is one of numerous cross-linked acrytic acid polymers that are given the general adopted name carbomer. These polymers dissolve in water and form a clear or slightly hazy gel upon neutralization with a caustic material such as sodium hydroxide, potassium hydroxide, triethanolamine, or other amine bases.
  • KLUCEL is a ceUulose polymer that is dispersed in water and forms a uniform gel upon complete hydration. Other preferred gelling polymers include hydroxyethylceUulose, ceUulose gum, MVEMA decadiene crosspolymer, PVM7MA copolymer, or a combination thereof.
  • Preservatives may also be used in this invention and preferably comprise about 0.05% to
  • preservatives assures that if the product is microbiaUy contaminated, the formulation wiU prevent or diminish microorganism growth.
  • Some preservatives useful in this invention include methylparaben, propylparaben, butylparaben, chloroxylenol, sodium benzoate, DMDM Hydantoin, 3-Iodo-2-Propylbutyl carbamate, potassium sorbate, chlorhexidine digluconate, or a combination thereof. Titanium dioxide may be used as a sunscreen to serve as prophylaxis against photosensitization.
  • Alternative sun screens include methyl cinnamate.
  • BHA may be used as an antioxidant, as weU as to protect ethoxydiglycol and/or dapsone from discoloration due to oxidation.
  • An alternate antioxidant is BHT.
  • Pharmaceuticals for use in aU embodiments of the invention include antimicrobial agents, anti-inflammatory agents, antiviral agents, local anesthetic agents, corticosteroids, destructive therapy agents, antifungals, and antiandrogens.
  • active pharmaceuticals that may be used include antimicrobial agents, especiaUy those having anti-inflammatory properties such as dapsone, erythromycin, minocycUne, tetracycline, clindamycin, and other antimicrobials.
  • the preferred weight percentages for the antimicrobials are 0.5% to 10%.
  • Local anesthetics include tetracaine, tetracaine hydrochloride, Udocaine, Udocaine hydrochloride, dyclonine, dyclonine hydrochloride, dimethisoquin hydrochloride, dibucaine, dibucaine hydrochloride, butambenpicrate, and pramoxine hydrochloride.
  • a preferred concentration for local anesthetics is about 0.025% to 5% by weight of the total composition.
  • Anesthetics such as benzocaine may also be used at a preferred concentration of about 2% to 25% by weight.
  • Corticosteroids that may be used include betamethasone dipropionate, fluocinolone actinide, betamethasone valerate, triamcinolone actinide, clobetasol propionate, desoximetasone, diflorasone diacetate, amcinonide, flurandrenolide, hydrocortisone valerate, hydrocortisone butyrate, and desonide are recommended at concentrations of about 0.01% to 1.0% by weight.
  • Preferred concentrations for corticosteroids such as hydrocortisone or methylprednisolone acetate are from about 0.2%> to about 5.0%> by weight.
  • Destructive therapy agents such as saUcyUc acid or lactic acid may also be used.
  • a concentration of about 2% to about 40% by weight is preferred.
  • Cantharidin is preferably utilized in a concentration of about 5% to about 30% by weight.
  • Typical antifungals that may be used in this invention and their preferred weight concentrations include: oxiconazole nitrate (0.1 % to 5.0%)), ciclopirox olamine (0.1% to 5.0%>), ketoconazole (0.1%> to 5.0%>), miconazole nitrate (0.1%) to 5.0%), and butoconazole nitrate (0.1% to 5.0%>).
  • the active pharmaceutical may include an antiandrogen such as flutamide or finasteride in preferred weight percentages of about 0.5% to 10%.
  • treatments using a combination of drugs include antibiotics in combination with local anesthetics such as polymycin B sulfate and neomycin sulfate in combination with tetracaine for topical antibiotic gels to provide prophylaxis against infection and reUef of pain.
  • local anesthetics such as polymycin B sulfate and neomycin sulfate in combination with tetracaine for topical antibiotic gels to provide prophylaxis against infection and reUef of pain.
  • minoxidil in combination with a corticosteroid such as betamethasone diproprionate for the treatment of alopecia ereata.
  • an anti-inflammatory such as cortisone
  • an antifungal such as ketoconazole for the treatment of tinea infections is also an example.
  • creams may be considered pharmaceutical compositions, and the detailed description of pharmaceutical compositions wiU be taken to be equaUy applicable to the creams containing the agents.
  • agent is administered or applied in the form of a patch comprising the agent or agents.
  • a patch comprising an agent capable of effecting the degradation of a component of the epidermal barrier of an individual.
  • a patch comprising a molecule to be deUvered to an individual together with an agent capable of effecting the degradation of a component of the epidermal barrier.
  • the use of such a patch for enabling or assisting the deUvery of a molecule to an individual is also provided.
  • the patch may comprise a cream (comprising an agent capable of reducing an epidermal barrier function, optionaUy together with a molecule or drug to be deUvered) as described above.
  • a cream comprising an agent capable of reducing an epidermal barrier function, optionaUy together with a molecule or drug to be deUvered
  • appUcation of such a cream to a conventional patch or bandage, as sold for example in a pharmacy, and appUcation of such a bandage or patch to the skin
  • a single patch comprising each agent may be used, or multiple patches each comprising a separate agent.
  • the or each patch may comprise the compound or molecule to be deUvered, as a mixture with the agent, or in a separate compartment from the agent.
  • this term should be taken to include reference to any preferably planar material capable of maintaining contact between a molecule retained therewith (such as an agent capable of degrading the epidermal barrier, or a drug to be deUvered) and the sldn of an individual.
  • such a patch is capable of occluding the agent, molecule, etc.
  • the patch may be permeable to other molecules such as gas, such as air, or water or other Uquid, or it may be substantiaUy impermeable to any or aU of these.
  • the patch is occlusive to gas or other molecules.
  • patch should be taken to include a simple bandage comprising for example cotton wool taped to an individual's skin, but preferably should be taken to include a simple patch, a Band- Aid, a surgical dressing, plasters, etc.
  • the patch comprises a transdermal patch.
  • Transdermal patches are known in the art.
  • the bandage comprising an adhesive, as in the case of a Band- Aid or by any other means, such as an elastic strap.
  • the bandage may comprise a compartment made of for example an absorbent material to retain the molecule to be administered.
  • the compartment is generally centrally positioned within the bandage, and may suitably be made of cotton wool or gauze.
  • Bandages come in a variety of shapes and sizes. They are used to cover and protect wounds such as cuts, abrasions, punctures, and other forms of wounds inflicted on human tissue such as the skin of the arms, legs, hands, and other parts of the human body.
  • a bandage comprises a flexible backing with an adhesive surface for attaching the bandage to the sldn.
  • the bandage may have a patch of gauze or absorbent material disposed at the centre of the adhesive surface.
  • Such adhesive bandages are weU-known and staple items in a first-aid kit or medicine cabinet.
  • the agent may be appUed to a bandage either directly or in one of the other carriers.
  • the bandages may be sold damp or dry, wherein the agent is in a lyophilized form on the bandage.
  • the bandage may be a time-release bandage.
  • a adhesive bandage includes a flexible backing, such as a strip of plastic material or woven or non-woven fabric or the like capable of receiving and retaining adhesive of the type normaUy employed for adhesive bandages.
  • the backing may be made of a material that is breathable, gas-permeable, and/or hydrophobic.
  • the backing may also contain one or more designs and colours and could also be made to look translucent, transparent, or opaque. These materials, their dimensions, modifications, etc., are weU known in the industry.
  • the backing may be in the shape of a strip having end portions extending from a central portion. A skin-contacting or bottom surface of the end portions is coated with an adhesive for attaching the bandage to the skin.
  • GeneraUy disposed at the central portion of the bottom surface of the flexible backing may be an absorbent pad, made of gauze, cotton, or some other absorbent material, that is meant for direct contact with the area of the skin where administration of the agent and/or molecule/compound is to be deUvered. This area is therefore void of adhesive on the skin-facing surface.
  • the agent is preferably held in the absorbent pad, optionaUy together with the compound, molecule or drug to be delivered.
  • the bandage comprises a mixture of the or each agent and the compound or molecule to be delivered.
  • the bandage comprises the compound or molecule to be deUvered in a separate compartment from the or each agent.
  • the separate compartments may comprise portions of an absorbent pad, or more than one absorbent pad.
  • the absorbent pad may comprise a first portion comprising the agent capable of reducing an epidermal barrier function, and a second portion comprising the molecule to be deUvered.
  • the first and second portion are such that the agent and the molecule/drag are substantiaUy separated, i.e., there is limited or preferably substantiaUy no diffusion or passage of molecules between the first portion and the second portion. This may be achieved by the presence of a physical barrier, such as a non-permeable membrane between the first and second portion.
  • the first portion and/or the second portion may be in the form of layers, which are disposed in the plane of the bandage.
  • the second portion may be disposed on the bandage so that it is sandwiched between the first portion and the backing of the bandage, i.e., disposed as follows: skin-first portion-second portion-backing.
  • the invention also relates to pharmaceutical compositions comprising one or more agents capable of reducing an epidermal barrier ftinction.
  • agents capable of reducing an epidermal barrier ftinction include agents capable of degrading a proteinaceous component of the epidermal barrier, and/or agents capable of degrading a lipidic component of the epidermal barrier, as described above
  • composition comprising the agent or agents to be administered alone, it is preferable to formulate the active ingredient(s) as a pharmaceutical formulation.
  • the composition may include the agent(s), a structuraUy related compound, or an acidic salt thereof.
  • the pharmaceutical formulations described here comprise an effective amount of agent together with one or more pharmaceuticaUy-acceptable carriers.
  • An "effective amounf ' of an agent is the amount sufficient to enable or assist transdermal deUvery of a relevant molecule, compound or drag, as the case may be.
  • the drag, etc is one which is suitable for administration to an individual suffering from a disease.
  • the effective amount of the agent may therefore vary between individuals, and may need to be taUored for different individuals.
  • Factors influencing the effective amount of the agent include in particular the degree of permeabiUty of the individual's skin to the drug, etc.
  • an individual is already suffering from a Group I disease as described above (whether or not this is a disease which is to be treated by administration of the drug, etc)
  • his sldn may exhibit decreased ceU-ceU adhesion and hence greater permeabiUty (lower degree of barrier function).
  • the effective amount of agent capable of reducing an epidermal barrier ftinction may be lower than for "normal" skin.
  • an individual suffering from a Group II disease wiU have enhanced barrier function, and the amount of agent capable of reducing an epidermal barrier ftinction wtil need to be increased for effectiveness.
  • a guide to an effective amount of agent is the amount needed for permeabiUty of the relevant drag, etc, in a "normal" (undiseased) skin; this amount may be increased or decreased according to the disease state of the individual.
  • Another factor which is important for determining the effective amount of agent capable of reducing an epidermal barrier function wiU be the molecular weight of the drug or molecule to be deUvered.
  • a higher molecular weight may mean that the effective amount of agent wiU be higher than normal, and vice versa.
  • Suitable pharmaceuticaUy acceptable carriers are weU known in the art and vary with the desired form and mode of administration of the pharmaceutical formulation. For example, they can include effluents or excipients such as fiUers, binders, wetting agents, disintegrators, surface- active agents, lubricants and the like.
  • the carrier is a soUd, a Uquid or a vaporizable carrier, or a combination thereof.
  • Each carrier should be "acceptable” in the sense of being compatible with the other ingredients in the formulation and not injurious to the individual.
  • the carrier should be biologicaUy acceptable without eUciting an adverse reaction (e.g. immune response) when administered to the host.
  • compositions include those suitable for topical and oral administration, with topical formulations being preferred where the tissue affected is primarily the sldn or epidermis (for example, psoriasis and other epidermal diseases).
  • the topical formulations include those pharmaceutical forms in which the composition is applied extemaUy by direct contact with the skin surface to be treated.
  • a conventional pharmaceutical form for topical application includes a soak, an ointment, a cream, a lotion, a paste, a gel, a stick, a spray, an aerosol, a bath oil, a solution and the Uke.
  • Topical therapy is deUvered by various vehicles, the choice of vehicle can be important and generally is related to whether an acute or chronic disease is to be treated.
  • an acute skin proUferation disease generally is treated with aqueous drying preparations, whereas chronic skin proliferation disease is treated with hydrating preparations.
  • Soaks are the easiest method of drying acute moist eruptions.
  • Lotions prowder in water suspension
  • solutions medications dissolved in a solvent
  • Ointments or water-in-oU emulsions are the most effective hydrating agents, appropriate for dry scaly eruptions, but are greasy and depending upon the site of the lesion sometimes undesirable. As appropriate, they can be appUed in combination with a bandage, particularly when it is desirable to increase penetration of the agent composition into a lesion.
  • Creams or oU- in-water emulsions and gels are absorbable and are the most cosmeticaUy acceptable to the individual. (Guzzo et al, in Goodman & Gilman's Pharmacological Basis of Therapeutics, 9th Ed., p. 1593-15950 (1996)).
  • Cream formulations generaUy include components such as petroleum, lanolin, polyethylene glycols, mineral oU, glycerin, isopropyl palmitate, glyceryl stearate, cetearyl alcohol, tocopheryl acetate, isopropyl myristate, lanolin alcohol, simethicone, carbomen, methylchlorisothiazolinone, methylisothiazolinone, cyclomethicone and hydroxypropyl methylceUulose, as weU as mixtures thereof.
  • compositions for topical application include shampoos, soaps, shake lotions, and the Uke, particularly those formulated to leave a residue on the underlying sldn, such as the scalp (Arndt et al, in Dermatology In General Medicine 2:2838 (1993)).
  • the concentration of the agent composition in the topical formulation is in an amount of about 0.5 to 50% by weight of the composition, preferably about 1 to 30%, more preferably about 2-20%), and most preferably about 5-10%.
  • the concentration used can be in the upper portion of the range initially, as treatment continues, the concentration can be lowered or the appUcation of the formulation may be less frequent.
  • Topical applications are often appUed twice daily. However, once-daUy application of a larger dose or more frequent appUcations of a smaller dose may be effective.
  • the stratum comeum may act as a reservoir and allow gradual penetration of a drag into the viable sldn layers over a prolonged period of time.
  • the pharmaceutical composition may further include, together with the agent capable of reducing an epidermal barrier function, a Icnown skin penetration enhancer.
  • sldn penetration enhancers include dimethyl sulfoxide (U.S. Pat. No. 3,711,602); oleic acid, 1,2-butanediol surfactant (Cooper, J. Pharm. Sci., 73:1153-1156 (1984)); a combination of ethanol and oleic acid or oleyl alcohol (EP 267,617), 2-ethyl-l,3-hexanediol (WO 87/03490); decyl methyl sulphoxide and Azone (Hadgraft, Eur. J. Drug. Metab.
  • the pharmaceutical composition may also include the drug to be deUvered, in combination with the agent capable of reducing an epidermal barrier function and optionaUy a known skin penetration enhancer.
  • the agent capable of reducing an epidermal barrier function may be suppUed in the form of a separate pharmaceutical composition from the drug.
  • Such a kit may further include instructions for administering the agent and the drug, according to the methods already described, for efficient penetration of the drug.
  • the topical formulations of this invention can have additional excipients for example; preservatives such as methylparaben, benzyl alcohol, sorbic acid or quaternary ammonium compound; stabilizers such as EDTA, antioxidants such as butylated hydroxytoluene or butylated hydroxanisole, and buffers such as citrate and phosphate.
  • preservatives such as methylparaben, benzyl alcohol, sorbic acid or quaternary ammonium compound
  • stabilizers such as EDTA, antioxidants such as butylated hydroxytoluene or butylated hydroxanisole, and buffers such as citrate and phosphate.
  • radiolabeUed molecules may be used to measure penetration through the composites.
  • this system is not quantitative and a Franz chamber method is preferable.
  • the Franz chamber is a standard method used to measure the penetration of drags and other xenobiotics through skin. This system may be modified by tape stripping the skin to reduce the integrity of the epidermal barrier.
  • the invention includes within its claims a method to allow the admimstration of vaccines via the transcutaneous route.
  • Vaccines have previously only been administered by injection below the skin eg. subdermal subcutaneous or intramuscular.
  • This invention transiently breaks down the skin barrier which permits the penetration of the vaccine into the systematic circulation. This then allows immunity to develop to the particular disease.
  • a further claim of the invention is a method to allow the admimstration of allergens via the transcutaneous route, in order to desensitise the individual to the allergens. Allergens have previously been administered via the subcutaneous route. This carries a significant risk of inducing an anaphylactic response. This invention transiently breaks down the skin barrier which permits the penetration of the allergen.
  • ANNEX A ADHESION PROTEINS, PROTEASES AND PROTEASE INHIBITORS
  • Tables Al, A2 and A2 detail adhesion proteins, proteases and protease inhibitors, with their GenBank accession numbers. Each of these adhesion proteins, proteases and protease inhibitors may be used in the methods and compositions described in this document.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un procédé d'administration d'une molécule à un individu consistant (a) à mettre en oeuvre un agent pouvant réaliser la dégradation d'un composant de la barrière épidermique de l'individu, (b) à administrer cet agent à l'individu, et (c) à administrer la molécule à l'individu. Elle concerne plus spécifiquement l'utilisation de protéolyse, et d'autres processus de dégradation pour la réduction de la fonction de barrière épidermique, afin de réguler le passage d'agents à travers le stratum corneum, puis dans le corps d'un individu. Un timbre contenant un agent, ou les deux agents à la fois, constitue un mode avantageux de réalisation de l'invention.
PCT/GB2002/005394 2001-11-29 2002-11-29 Traitement de maladies Ceased WO2003047629A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002365654A AU2002365654A1 (en) 2001-11-29 2002-11-29 Treatment of diseases via the skin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0128629.3 2001-11-29
GB0128629A GB0128629D0 (en) 2001-11-29 2001-11-29 Method

Publications (2)

Publication Number Publication Date
WO2003047629A2 true WO2003047629A2 (fr) 2003-06-12
WO2003047629A3 WO2003047629A3 (fr) 2003-08-28

Family

ID=9926699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/005394 Ceased WO2003047629A2 (fr) 2001-11-29 2002-11-29 Traitement de maladies

Country Status (3)

Country Link
AU (1) AU2002365654A1 (fr)
GB (1) GB0128629D0 (fr)
WO (1) WO2003047629A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015144183A1 (fr) * 2014-03-26 2015-10-01 University Of Copenhagen Traitement de la dermatite de contact

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556218B1 (fr) * 1983-12-12 1986-11-14 Gerard Alain Produit pharmaceutique pour application locale constitue par l'association d'un principe actif medicamenteux-agent enzymatique
AU5190790A (en) * 1989-02-23 1990-09-26 University Of Utah, The Percutaneous drug delivery system
JPH0344310A (ja) * 1989-07-10 1991-02-26 Mareyoshi Sawaguchi マコモ及びその近縁類を含有する化粧品
DK72593D0 (da) * 1993-06-18 1993-06-18 Symbicom Ab Rekombinant protein
IE990935A1 (en) * 1999-11-08 2002-04-03 Procter & Gamble Cosmetic Compositions
KR100338327B1 (ko) * 2000-05-16 2002-08-07 주식회사 태평양 피부 외용제 내의 활성성분의 피부 흡수를 증진시킬 수있는 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015144183A1 (fr) * 2014-03-26 2015-10-01 University Of Copenhagen Traitement de la dermatite de contact

Also Published As

Publication number Publication date
AU2002365654A8 (en) 2003-06-17
WO2003047629A3 (fr) 2003-08-28
GB0128629D0 (en) 2002-01-23
AU2002365654A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
EP2809341B1 (fr) Compositions enzymatiques et leur utilisation pour la cicatrisation
Petrova et al. Advances in understanding of Netherton syndrome and therapeutic implications
US8795654B2 (en) Methods for improving the tissue penetration of a drug by administering the drug together with a hyaluronidase protein
US11617785B2 (en) Treatment of inflammatory skin disorders
JP2018009026A (ja) 経皮送達
JP6140120B2 (ja) 挫瘡およびその他の状態を治療するためのビスファチン治療薬
KR20150009521A (ko) 국소피부제제 및 개인맞춤형 피부치료방법
KR19980702081A (ko) 다기능성 효소
CA2508796A1 (fr) Preparations antiinfectieuses topiques
EP4054713A1 (fr) Compositions et méthodes de traitement ou de prévention de maladies et de troubles cutanés au moyen de lekti
Tombulturk et al. A molecular approach to maggot debridement therapy with Lucilia sericata and its excretions/secretions in wound healing
KR20210075218A (ko) 세타-디펜신들로 염증성 프로테아제들의 차단
AU742294B2 (en) A method of biological control
WO2022261498A1 (fr) Dispositif et méthodes de traitement de l'acné : bactériophages antibactériens et lysines modifiées
Sun et al. Long-term and potent IOP-lowering effect of IκBα-siRNA in a nonhuman primate model of chronic ocular hypertension
Thomas-Virnig et al. Inhibition of multidrug-resistant Acinetobacter baumannii by nonviral expression of hCAP-18 in a bioengineered human skin tissue
EP3960190A1 (fr) Utilisation d'un squelette de paroi cellulaire de nocardia rubra dans le traitement d'une brûlure thermique
KR102863855B1 (ko) 프로테아제의 단백질 분해 활성의 강화 및 안정화
WO2003047629A2 (fr) Traitement de maladies
DE10121255A1 (de) Verwendung von alpha 1-Antichymotrypsin Polypeptiden oder diese kodierende Nukleinsäuren, oder einer ein ACT Polypeptid oder diese kodierende Nukleinsäure exprimierende Zelle, zur Behandlung und/oder Prävention von diabetes-assoziierten und/oder arteriellen schlecht heilenden Wunden und zur Identifizierung von pharmakologisch aktiven Substanzen
US11331356B2 (en) Preparation with the mycoparasitic microorganism pythium oligandrum for the treatment of dermaphytoses and yeast infections on the skin and mucouses, method of determing the cell's viability of the microorganism pythium oligandrum and method of applying the preparation
Widowati et al. Potential antiaging activity of secretome gel of human Wharton’s jelly mesenchymal stem cells (hWJ-MSCs) in UV-induced mice models
TWI548415B (zh) 狗圍肛腺瘤之治療方法
CN101541829A (zh) 来自丝光绿蝇的胰凝乳蛋白酶及其在治疗伤口中的用途
Rao et al. Net Quiz-Inflammatory pruritic nodules and plaques on the face

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP